2020
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure
DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. JAMA Cardiology 2020, 5: 202-207. PMID: 31825471, PMCID: PMC6990764, DOI: 10.1001/jamacardio.2019.4665.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsDrug CombinationsEnalaprilFemaleHeart FailureHospitalizationHumansMaleMiddle AgedNatriuretic Peptide, BrainNeprilysinPatient DischargePeptide FragmentsTetrazolesValsartanConceptsAcute decompensated heart failureSacubitril/valsartanNT-proBNP levelsDecompensated heart failureOpen-label studyReduced ejection fractionHospital initiationHeart failurePIONEER-HFEjection fractionWeek 8N-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsOpen-label extension phaseAngiotensin-Neprilysin InhibitionHeart failure rehospitalizationPIONEER-HF trialWeek 8 visitNatriuretic peptide levelsActive-controlled trialCardiovascular deathComposite outcomeHemodynamic stabilityRecent hospitalizationClinical outcomes
2019
Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study
Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E. Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal Of Cardiac Failure 2019, 26: 371-380. PMID: 31682908, PMCID: PMC7195219, DOI: 10.1016/j.cardfail.2019.10.011.Peer-Reviewed Original ResearchConceptsDiastolic dysfunctionBody mass indexAntiretroviral therapyN-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsHuman immunodeficiency virus-infected individualsCross-sectional case-control studyLow-density lipoprotein levelsHigher body mass indexHigh-sensitivity troponin IHIV RNA copiesSignificant valvular diseaseNatriuretic peptide levelsHigher interleukin-6Normal ejection fractionVirus-infected individualsLeft atrial sizePersistent atrial fibrillationProgressive cardiac remodelingSymptom frequency scoreAntiretroviral Therapy studyCardiac magnetic resonanceCase-control studyCarboxyl-terminal telopeptideCD4 count